AI-enabled pharmaceutical R&D market growing quickly
This image was generated by AI and may not depict real events.
The AI-enabled pharmaceutical R&D market is growing rapidly, with Chinese companies XtalPi and InSilico Medicine adopting different business models. XtalPi focuses on selling AI-powered research services, while InSilico uses algorithms to create new biotech pipelines.
The AI drug discovery sector is still defining its commercial models, with Chinese companies making significant strides. XtalPi and InSilico Medicine have adopted different approaches, with XtalPi selling AI-powered research services and InSilico creating new biotech pipelines. XtalPi reported revenue of $111 million in 2025, a 201.2% year-on-year increase, and posted its first full-year net profit. In contrast, InSilico generated $56.2 million in revenue but reported an adjusted net loss of $43.8 million. The difference highlights a broader debate on whether AI should be commercialized as a research platform or as the foundation for building biotech companies. XtalPi's core business combines AI-driven molecular simulation with automated laboratories and robotics systems to accelerate early-stage drug discovery.
This content was automatically generated and/or translated by AI. It may contain inaccuracies. Please refer to the original sources for verification.